Stanford Medicine has recently made a significant breakthrough in the field of Hodgkin lymphoma treatment. A new blood test, developed by the institution’s researchers, promises to predict recurrence and divide the disease into two subgroups, potentially leading to new drug targets and improved patient outcomes.
The new blood test, which analyzes circulating tumor DNA, has been shown to split Hodgkin lymphoma into two subgroups in a Stanford Medicine-led study. This innovative approach could lead to the identification of new drug targets, potentially improving the lives of countless patients. The blood test has also been demonstrated to predict recurrence. This capability offers new hope for patients and their families, potentially leading to improved outcomes and a brighter future for those affected by the disease.